Pharmacological or TRIB3-Mediated Suppression of ATF4 Transcriptional Activity Promotes Hepatoma Cell Resistance to Proteasome Inhibitor Bortezomib

SIMPLE SUMMARY: Proteasome inhibitors are currently used in the treatment of certain blood cancers, and clinical trials to treat solid tumors, including liver cancer, have also been conducted. However, different malignancies are not equally susceptible to proteasome inhibitors, and resistance to the...

Descripción completa

Detalles Bibliográficos
Autores principales: Örd, Tiit, Örd, Daima, Kaikkonen, Minna U., Örd, Tõnis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8150958/
https://www.ncbi.nlm.nih.gov/pubmed/34066165
http://dx.doi.org/10.3390/cancers13102341

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8150958/
https://www.ncbi.nlm.nih.gov/pubmed/34066165
http://dx.doi.org/10.3390/cancers13102341

Ejemplares similares